Competition & Markets Authority
Pharmaceutical merger cleared by CMA
The CMA has cleared the anticipated purchase of gene therapy company Spark Therapeutics by pharmaceutical company Roche Holdings.
Both companies develop treatments that aim to prevent bleeding in patients with Haemophilia A, a genetic blood disorder. The Competition and Markets Authority (CMA) has been examining whether the deal could negatively affect the future treatment choices available to the NHS, doctors and patients.
Roche supplies a drug called Hemlibra, a relatively-recent market entrant that has already become recognised as an important and innovative medicine for patients in the UK. Spark is in the process of developing a gene therapy treatment for Haemophilia A that is expected to compete with Hemlibra in future.
The CMA’s initial Phase 1 investigation found that the supply of Haemophilia A treatments is a developing sector in which a number of suppliers are in the process of bringing new products to market.
While gene therapy treatments are likely to compete with Roche’s Hemlibra in future, the CMA found that Spark is not the only supplier developing a gene therapy treatment and that its products are not currently considered to hold any particular clinical or commercial advantages over those being developed by other suppliers.
The CMA’s investigation also found that there are several innovative non-gene therapy products under development that are likely to become viable alternatives to Roche and Spark’s treatments.
The CMA therefore found that the deal between Roche and Spark would not negatively affect competition because UK health services and patients will still have an adequate choice of alternatives.
The deal is also being investigated by the US Federal Trade Commission and the 2 authorities have cooperated closely.
More information can be found on the CMA’s Roche Holdings/Spark Therapeutics inquiry page.
Latest News from
Competition & Markets Authority
Provisional findings published in CMA review of water price controls30/09/2020 12:20:00
The CMA is consulting on its provisional findings from its redetermination of Ofwat’s proposed 2020-25 price controls.
Private healthcare provider fixed prices with consultants25/09/2020 12:20:00
Lessons from the CMA’s investigation into Spire Healthcare's illegal agreement to fix the price of initial consultations for private self-pay patients.
CMA acts to protect competition on UK-US airline routes18/09/2020 09:20:00
Due to coronavirus, the CMA has imposed measures to protect competition on UK-US air routes while it investigates an agreement involving BA and American Airlines.
Motorcycle insurance broker merger raises competition concerns17/09/2020 09:20:00
The CMA has found that Ardonagh’s completed purchase of Bennetts could lead to higher prices, less choice and worse services for motorcyclists in the UK.
TUI UK to complete refunds by the end of the month16/09/2020 12:25:00
TUI UK has committed to the CMA that customers awaiting their refunds for holidays that were cancelled due to coronavirus will receive them by the end of the month.
Final decision published in window blind merger inquiry15/09/2020 09:20:00
The CMA has decided that Hunter Douglas, owner of online blinds retailer Blinds2Go, must sell the majority of its shares in 247 to protect competition and prevent higher prices.
Digital advertising merger to be abandoned during CMA investigation14/09/2020 13:25:00
Taboola has announced that it is to abandon its proposed purchase of Outbrain.
CMA updates competition law risk guide for managers11/09/2020 09:20:00
An updated guide to competition rules has been issued to help managers, directors and their advisers to stay on the right side of the law.